Integer (NYSE:ITGR) Posts Earnings Results, Misses Expectations By $0.03 EPS

Integer (NYSE:ITGR - Get Free Report) announced its quarterly earnings results on Thursday. The medical equipment provider reported $1.43 earnings per share for the quarter, missing analysts' consensus estimates of $1.46 by ($0.03), Zacks reports. The company had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. Integer updated its FY 2025 guidance to 5.840-6.200 EPS.

Integer Trading Down 3.9 %

Shares of ITGR stock traded down $5.26 on Friday, hitting $129.96. The stock had a trading volume of 499,343 shares, compared to its average volume of 252,248. The company has a fifty day moving average price of $137.92 and a two-hundred day moving average price of $132.31. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The firm has a market cap of $4.36 billion, a P/E ratio of 40.11, a PEG ratio of 1.82 and a beta of 1.13. Integer has a twelve month low of $98.63 and a twelve month high of $146.36.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ITGR shares. Citigroup increased their target price on shares of Integer from $130.00 to $145.00 and gave the stock a "neutral" rating in a research report on Wednesday, December 11th. Oppenheimer cut Integer from an "outperform" rating to a "market perform" rating in a report on Friday. Wells Fargo & Company reiterated an "overweight" rating and set a $160.00 price target on shares of Integer in a research report on Tuesday, December 3rd. KeyCorp increased their price target on shares of Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $140.00 price objective (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Integer has a consensus rating of "Moderate Buy" and a consensus price target of $147.67.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.